ImmunityBio

IPO

Immunotherapy by ImmunityBio - Cancer Vaccine Research

Public · Culver City, United States · Founded 2014 · $180.0M raised

Employees
201–500
Founded
2014
Business Model
B2B
Total Funding
$180.0M
Last Round
$100.0M Venture RoundDec 2025
Rounds
3
Type
Public

About

ImmunityBio develops next-generation immunotherapies that activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product ANKTIVA received FDA approval in 2024 for non-muscle invasive bladder cancer, and the company applies a 'triangle offense' strategy stimulating NK cells, T cells, macrophages, and dendritic cells to create durable immune responses.

Summary

ImmunityBio is a Biotech company based in Culver City, United States, founded in 2014. It has raised $180.0M in total across 3 rounds, most recently a $100.0M Venture Round round in Dec 2025. Investors include Oberland Capital.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Venture RoundVenture RoundDec 2025
$100.0M

Sign up to see all 4 rounds

Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ImmunityBio on Indexed.vc
<a href="https://indexed.vc/companies/immunitybio"><img src="https://indexed.vc/api/badge/company/immunitybio" alt="ImmunityBio on Indexed.vc" width="260" height="76" /></a>